UK regulatory authorities approved molnupiravir to treat patients with mild-to-moderate COVID-19.
Formulary Watch
Latest News
All News
Advertisement
This Tufts study has found that plans that restrict orphan drugs do so by narrowing the patient population who can receive them.
Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.
The agency needs more time to review new information on the analytical method used.
Several generics of the cancer therapeutic are available.
But groups such as Doctors Without Borders say the agreement with the Medicines Patent Pool excludes key manufacturing countries.
EmsanaRx, the new PBM, aims to provide large employers with flexibility and transparency on drug spending.
Vuity, developed by Allergan, is a once-daily eye drop to treat presbyopia.
Novartis’ Scemblix was approved for previously treated patients and for those who are resistant to TKI inhibitors.
Advertisement
The dose is one-third of the dose given to people 12 years and older.
Some have expressed concerns about the risk of myocarditis and unknown longer-term side effects.
Dexamethasone is recommended by the NIH and the World Health Organization for treating COVID-19.
Specialty drug prices are rising as these therapeutics replace lower-cost therapies.
Novatis is seeking approval for Kymriah in adult patients with advanced follicular lymphoma.
The phase 2/3 trial showed a favorable safety profile, robust immune responses and a vaccine efficacy rate of 90.7% in children 5 to 11 years of age.
Seglentis’ co-crystal formulation targets four complementary pain relief mechanisms.
The label now includes new data from the trial that supported Cyltezo’s application for interchangeability with Humira.
Cigna plans to remove 45 drugs from its Standard Prescription Drug List and add restrictions for other therapeutics.
Cumulative spending on drugs without overall survival data was $1.8 billion in 2018 and surpassed that of drugs with such data.
Xipere is delivered via an injection to the back of the eye to treat macular edema associated with uveitis, a form of eye inflammation.
Specialty medicines are now 53% of spending, up from 27% in 2010 and driven by growth in autoimmune and oncology therapies.
Genentech’s Susvimo is a refillable implant that delivers medication continuously for up to six months.
Oncopeptides will close down its business units in the United States and Europe to focus exclusively on being a Sweden-based R&D company.
Developed by Regeneron Pharmaceuticals and Sanofi, Dupixent reduced severe asthma attacks and improved lung function in children 6 to 11 years.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Tubeless AID Systems Boost HRQoL in Type 1 Diabetes
2
Sonye Danoff, M.D., Ph.D., Discusses the FIBRONEER Study for IPF
3
Current Guideline Definitions of Barrett’s Esophagus May Fall Short in Detecting Esophageal Cancers
4
U.S. Lung Cancer Survival Improves to Nearly 30%, but Funding Cuts Threaten Progress
5
